MariMed Reports Fourth Quarter and Full Year 2025 Earnings
Executive Summary
- MariMed reported FY 2025 revenue of $159.8 M (up 1.3% YoY) and a sixth consecutive year of positive Adjusted EBITDA ($16.9 M), despite ongoing pricing pressure.
- The company announced several strategic moves: a licensing agreement to enter New York, exit from Missouri, new manufacturing/distribution agreements for the Vibations™ beverage brand in Rhode Island (2026), and a restructuring of its $14.725 M Series B convertible preferred stock extending maturity to 4.6 years.
- Liquidity improved with cash & equivalents rising to $8.9 M; total liabilities decreased modestly, while goodwill increased to $24.0 M reflecting recent acquisitions.
Key Details
- Financial Highlights (FY 2025 vs. FY 2024)
- Revenue: $159.8 M vs. $157.7 M (+1.3%).
- GAAP Gross margin: 36% vs. 40% (down).
- Non‑GAAP Gross margin: 41% vs. 43% (down).
- GAAP Net loss: $(14.5) M vs. $(12.4) M (wider).
- Non‑GAAP Adjusted EBITDA: $16.9 M vs. $19.3 M (down).
-
Adjusted EBITDA margin remained at ~11%.
-
Quarterly Highlights (Q4 2025)
- Wholesale revenue grew 11%; distribution now covers 85% of dispensaries in core markets.
- Betty’s Eddies™ ranked #1 edible in MA, MD, DE, IL.
-
Completed restructuring of Series B obligation, extending maturity by 4.6 years.
-
Strategic Agreements
- Oct 23: Licensing agreement with Farm 2 Hand, LLC to distribute MariMed products throughout New York pending kitchen build‑out and regulatory approvals.
- Oct 28: Exit from Missouri market to reallocate capital to higher‑return core markets.
-
Nov 3: Manufacturing & distribution agreements for Vibations™ beverage brand launch in the hemp‑derived THC market, starting with Rhode Island in 2026.
-
Restructuring Transaction (Mar 2)
- Restructuring and Exchange Agreement with holders of $14.725 M Series B Convertible Preferred Stock.
-
Eliminated mandatory conversion date (Feb 28 2026) and replaced it with longer‑dated instruments, extending weighted‑average maturity to 4.6 years, reducing near‑term refinancing risk.
-
Liquidity & Balance Sheet
- Cash & cash equivalents: $8.884 M (up from $7.282 M).
- Total assets: $202.565 M vs. $206.989 M prior year.
- Total liabilities: $137.831 M vs. $129.442 M prior year; increase driven by higher mortgage & note balances.
-
Mezzanine equity (Series B) remains at $14.725 M after restructuring.
-
Cash Flow Summary (FY 2025)
- Operating cash provided: $7.695 M (vs. $6.785 M YoY).
- Investing cash used: $(1.380 M) (significantly lower outflow than prior year).
-
Financing cash used: $(4.713 M), primarily mortgage repayments and principal payments on promissory notes; distributions of $(137 K).
-
Conference Call – Scheduled for Thursday, March 12 2026 at 8:00 a.m. ET; access via company IR website.
Notable Quotes
- Jon Levine, CEO: “We’re pleased to report record revenues as well as positive adjusted EBITDA for the sixth consecutive year… Our brands continue to resonate with our customers…”
- Mario Pinho, CFO: “Our clean balance sheet contains no material debt maturities in the near‑term, positioning us to execute growth without capital pressure.”
Materiality Assessment
Material – Positive – The release provides comprehensive FY 2025 financial results, key operational metrics, and significant strategic transactions that are likely to influence investor decisions.